Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study

AIMS: The purpose of this study was to examine the effectiveness of beinaglutide on body weight, glycated haemoglobin (HbA(1c)), blood pressure and lipid profiles in patients with type 2 diabetes mellitus (T2DM) in a real‐world setting in China. MATERIALS AND METHODS: This was a multicentre, observational, retrospective, open‐label study conducted in China. Data were collected from T2DM patients who started treatment with beinaglutide between 2017 and 2018. RESULTS: A total of 314 patients were included in the study. After 3 months of treatment with beinaglutide, there were significant reductions in body weight (−10.05 kg [95% confidence interval −9.29 to −10.80]), HbA(1c) (−2.87% [−2.62 to −3.11]), 2‐h postprandial plasma glucose (−5.46 mmol L(−1) [−4.96 to −5.95]) and fasting plasma glucose (−3.04 mmol L(−1) [−2.78 to −3.31]) (all p < 0.0001). In addition, 84.96% and 72.18% of the patients achieved weight loss of ≥5% and ≥10%, respectively. Subgroup analyses showed that weight loss was significantly greater in patients with ≥28 kg m(−2) of baseline body mass index and 0.60 mg of beinaglutide doses (p = 0.007 and p < 0.0001, respectively). HbA(1c) reductions were significantly greater in patients with ≥9.0% baseline HbA(1c) and in those administered 0.40–0.48 mg of beinaglutide doses (all p < 0.0001). Weight loss at 3 months was positively correlated with baseline BMI and the dose of beinaglutide. Positive determinants for HbA(1c) reduction after 3 months were baseline HbA(1c) and the dose of beinaglutide. CONCLUSIONS: These observational results confirmed the benefits of beinaglutide in weight loss and glycaemic control and support the use of beinaglutide as an effective treatment for T2DM.